
Medpace Holdings MEDP
$ 585.24
0.47%
Quarterly report 2025-Q3
added 10-23-2025
Medpace Holdings Book Value 2011-2026 | MEDP
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Medpace Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 826 M | 559 M | 386 M | 953 M | 806 M | 726 M | 590 M | 504 M | 611 M | 413 M | 402 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 953 M | 386 M | 616 M |
Quarterly Book Value Medpace Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 294 M | 172 M | 594 M | 826 M | 881 M | 764 M | 672 M | 559 M | 471 M | 391 M | 347 M | 386 M | 350 M | - | 605 M | 953 M | 898 M | 852 M | 859 M | 806 M | 806 M | 806 M | 806 M | 726 M | 726 M | 726 M | 726 M | 590 M | 590 M | 590 M | 590 M | 504 M | 504 M | 504 M | 504 M | 611 M | 611 M | 611 M | 611 M | 413 M | 413 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 953 M | 172 M | 616 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 38.83 | 14.0 % | $ 442 M | ||
|
Brainsway Ltd.
BWAY
|
75.7 M | $ 23.3 | -0.34 % | $ 99.4 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 39.38 | -0.03 % | $ 1.09 B | ||
|
BioNano Genomics
BNGO
|
35.4 M | $ 1.26 | -2.69 % | $ 1.6 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | $ 102.49 | 0.14 % | $ 19 B | ||
|
Co-Diagnostics
CODX
|
86 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
77.5 B | $ 222.92 | 1.85 % | $ 163 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Guardant Health
GH
|
-140 M | $ 114.77 | 0.64 % | $ 14.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
2.07 B | $ 72.79 | -0.34 % | $ 28.1 B | ||
|
CareDx, Inc
CDNA
|
261 M | $ 20.29 | -1.27 % | $ 1.09 B | ||
|
Celcuity
CELC
|
116 M | $ 111.76 | 2.14 % | $ 4.41 B | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.74 | 7.19 % | $ 305 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 26.0 | -0.76 % | $ 786 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 66.88 | -0.07 % | $ 4.63 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
IDEXX Laboratories
IDXX
|
1.6 B | $ 636.25 | -5.1 % | $ 52.5 B | ||
|
NeoGenomics
NEO
|
902 M | $ 12.25 | 1.53 % | $ 1.55 B | ||
|
Illumina
ILMN
|
6.3 B | $ 140.65 | -2.87 % | $ 22.4 B | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
National Research Corporation
NRC
|
49 M | $ 21.87 | 7.5 % | $ 537 M | ||
|
IQVIA Holdings
IQV
|
6.07 B | $ 230.93 | 0.34 % | $ 41.9 B | ||
|
Charles River Laboratories International
CRL
|
3.51 B | $ 212.06 | 0.7 % | $ 10.9 B | ||
|
Koninklijke Philips N.V.
PHG
|
12 B | $ 28.84 | 0.47 % | $ 20 B | ||
|
Precipio
PRPO
|
14.4 M | $ 24.75 | 0.9 % | $ 32.1 M | ||
|
Personalis
PSNL
|
203 M | $ 9.28 | -0.96 % | $ 550 M | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 184.48 | -1.33 % | $ 20.5 B | ||
|
Biodesix
BDSX
|
20.9 M | $ 10.24 | 0.69 % | $ 1.33 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.07 B | $ 269.19 | -0.86 % | $ 22.6 B | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 176.3 | -2.19 % | $ 14.5 B | ||
|
Agilent Technologies
A
|
5.39 B | $ 134.7 | 0.62 % | $ 40.9 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.39 | 0.63 % | $ 5.49 M | ||
|
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | ||
|
Bioventus
BVS
|
221 M | $ 8.23 | 3.78 % | $ 516 M |